a HBV DNA Ο½7 Ο« 10 5 copies/mL by bDNA assay Ο© loss of HBeAg (Study AI463022) or normalization of ALT (Study AI463027). b HBV DNA Ο½7 Ο« 10 5 copies/mL by bDNA assay. c HBV DNA Υ7 Ο« 10 5 copies/mL by bDNA assay.
Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients
β Scribed by R. Jardi; F. Rodriguez-Frias; M. Schaper; G. Ruiz; I. Elefsiniotis; R. Esteban; M. Buti
- Book ID
- 108886032
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 54 KB
- Volume
- 0
- Category
- Article
- ISSN
- 1352-0504
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Several mutations (V521L, P525L, L528M, T532S, and V555I) in the gene for hepatitis B virus (HBV) polymerase have been identified in HBV isolated from patients that displayed break-through viremia during famciclovir treatment. To determine whether these mutations cause phenotypic resistance to famci
Resistance mutations to hepatitis C virus (HCV) nonstructural protein 3 (NS3) protease inhibitors in <1% of the viral quasispecies may still allow >1000-fold viral load reductions upon treatment, consistent with their reported reduced replicative fitness in vitro. Recently, however, an R155K proteas